IT201800020383A1 - XOS corn cob derivatives to enhance the bioavailability and stability of raw materials in the production of nutraceuticals - Google Patents
XOS corn cob derivatives to enhance the bioavailability and stability of raw materials in the production of nutraceuticals Download PDFInfo
- Publication number
- IT201800020383A1 IT201800020383A1 IT102018000020383A IT201800020383A IT201800020383A1 IT 201800020383 A1 IT201800020383 A1 IT 201800020383A1 IT 102018000020383 A IT102018000020383 A IT 102018000020383A IT 201800020383 A IT201800020383 A IT 201800020383A IT 201800020383 A1 IT201800020383 A1 IT 201800020383A1
- Authority
- IT
- Italy
- Prior art keywords
- preparation according
- extract
- group
- functional
- xos
- Prior art date
Links
- 240000008042 Zea mays Species 0.000 title claims description 8
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 title claims description 8
- 235000002017 Zea mays subsp mays Nutrition 0.000 title claims description 8
- 235000005822 corn Nutrition 0.000 title claims description 8
- 238000004519 manufacturing process Methods 0.000 title description 6
- 239000002417 nutraceutical Substances 0.000 title description 4
- 235000021436 nutraceutical agent Nutrition 0.000 title description 4
- 239000002994 raw material Substances 0.000 title description 3
- 238000002360 preparation method Methods 0.000 claims description 55
- 239000000203 mixture Substances 0.000 claims description 51
- 238000009472 formulation Methods 0.000 claims description 50
- 239000000284 extract Substances 0.000 claims description 21
- 230000003078 antioxidant effect Effects 0.000 claims description 16
- 239000003963 antioxidant agent Substances 0.000 claims description 15
- 235000006708 antioxidants Nutrition 0.000 claims description 15
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 13
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 10
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 10
- 235000016804 zinc Nutrition 0.000 claims description 10
- 239000011701 zinc Substances 0.000 claims description 10
- 229910052725 zinc Inorganic materials 0.000 claims description 10
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 9
- 229920001542 oligosaccharide Polymers 0.000 claims description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 8
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 8
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 8
- 235000012661 lycopene Nutrition 0.000 claims description 8
- 229960004999 lycopene Drugs 0.000 claims description 8
- 239000001751 lycopene Substances 0.000 claims description 8
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 8
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 8
- HSTZMXCBWJGKHG-UHFFFAOYSA-N (E)-piceid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(C=CC=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-UHFFFAOYSA-N 0.000 claims description 7
- 102000004877 Insulin Human genes 0.000 claims description 7
- 108090001061 Insulin Proteins 0.000 claims description 7
- -1 aminosaccharides Substances 0.000 claims description 7
- 230000000844 anti-bacterial effect Effects 0.000 claims description 7
- 229940125396 insulin Drugs 0.000 claims description 7
- 229960003764 polydatin Drugs 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- HSTZMXCBWJGKHG-CUYWLFDKSA-N trans-piceid Polymers O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-CUYWLFDKSA-N 0.000 claims description 7
- 229940088594 vitamin Drugs 0.000 claims description 7
- 229930003231 vitamin Natural products 0.000 claims description 7
- 235000013343 vitamin Nutrition 0.000 claims description 7
- 239000011782 vitamin Substances 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 6
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 6
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 6
- 235000013361 beverage Nutrition 0.000 claims description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 6
- 239000011707 mineral Substances 0.000 claims description 6
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 6
- 239000003921 oil Substances 0.000 claims description 6
- 239000011669 selenium Substances 0.000 claims description 6
- 229910052711 selenium Inorganic materials 0.000 claims description 6
- 235000011649 selenium Nutrition 0.000 claims description 6
- 235000000346 sugar Nutrition 0.000 claims description 6
- 239000013589 supplement Substances 0.000 claims description 6
- 240000002900 Arthrospira platensis Species 0.000 claims description 5
- 235000016425 Arthrospira platensis Nutrition 0.000 claims description 5
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 5
- 235000017803 cinnamon Nutrition 0.000 claims description 5
- 239000002537 cosmetic Substances 0.000 claims description 5
- 230000037149 energy metabolism Effects 0.000 claims description 5
- 235000019152 folic acid Nutrition 0.000 claims description 5
- 239000011724 folic acid Substances 0.000 claims description 5
- 229960000304 folic acid Drugs 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- 210000000987 immune system Anatomy 0.000 claims description 5
- 238000006116 polymerization reaction Methods 0.000 claims description 5
- 201000004384 Alopecia Diseases 0.000 claims description 4
- 208000006820 Arthralgia Diseases 0.000 claims description 4
- 241000196324 Embryophyta Species 0.000 claims description 4
- JUUBCHWRXWPFFH-UHFFFAOYSA-N Hydroxytyrosol Chemical compound OCCC1=CC=C(O)C(O)=C1 JUUBCHWRXWPFFH-UHFFFAOYSA-N 0.000 claims description 4
- 239000005639 Lauric acid Substances 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 235000005318 Serenoa repens Nutrition 0.000 claims description 4
- 240000006661 Serenoa repens Species 0.000 claims description 4
- 240000001717 Vaccinium macrocarpon Species 0.000 claims description 4
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 claims description 4
- 239000003905 agrochemical Substances 0.000 claims description 4
- 235000004634 cranberry Nutrition 0.000 claims description 4
- 235000013376 functional food Nutrition 0.000 claims description 4
- 229910052742 iron Inorganic materials 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 238000005728 strengthening Methods 0.000 claims description 4
- 230000001256 tonic effect Effects 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 3
- 244000187129 Bacopa monnieria Species 0.000 claims description 3
- 235000015418 Bacopa monnieria Nutrition 0.000 claims description 3
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims description 3
- 241000178343 Butea superba Species 0.000 claims description 3
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 3
- 208000035484 Cellulite Diseases 0.000 claims description 3
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- 241000195493 Cryptophyta Species 0.000 claims description 3
- 208000001840 Dandruff Diseases 0.000 claims description 3
- 244000119298 Emblica officinalis Species 0.000 claims description 3
- 235000015489 Emblica officinalis Nutrition 0.000 claims description 3
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 3
- 235000005206 Hibiscus Nutrition 0.000 claims description 3
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 claims description 3
- 244000284380 Hibiscus rosa sinensis Species 0.000 claims description 3
- 239000005909 Kieselgur Substances 0.000 claims description 3
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 3
- 206010049752 Peau d'orange Diseases 0.000 claims description 3
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 3
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- 244000274883 Urtica dioica Species 0.000 claims description 3
- 235000009108 Urtica dioica Nutrition 0.000 claims description 3
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 3
- 244000078534 Vaccinium myrtillus Species 0.000 claims description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 230000000843 anti-fungal effect Effects 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 3
- 229910052804 chromium Inorganic materials 0.000 claims description 3
- 239000011651 chromium Substances 0.000 claims description 3
- 235000012721 chromium Nutrition 0.000 claims description 3
- 229960002173 citrulline Drugs 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims description 3
- 239000003337 fertilizer Substances 0.000 claims description 3
- 208000024963 hair loss Diseases 0.000 claims description 3
- 230000003676 hair loss Effects 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 201000001881 impotence Diseases 0.000 claims description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 3
- 229940016409 methylsulfonylmethane Drugs 0.000 claims description 3
- 230000000813 microbial effect Effects 0.000 claims description 3
- 230000004065 mitochondrial dysfunction Effects 0.000 claims description 3
- 229960002446 octanoic acid Drugs 0.000 claims description 3
- 235000005875 quercetin Nutrition 0.000 claims description 3
- 229960001285 quercetin Drugs 0.000 claims description 3
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims description 3
- 235000021283 resveratrol Nutrition 0.000 claims description 3
- 229940016667 resveratrol Drugs 0.000 claims description 3
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims description 3
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims description 3
- 235000005493 rutin Nutrition 0.000 claims description 3
- 229960004555 rutoside Drugs 0.000 claims description 3
- 229940112950 sage extract Drugs 0.000 claims description 3
- 235000020752 sage extract Nutrition 0.000 claims description 3
- 229940082787 spirulina Drugs 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 3
- 235000005282 vitamin D3 Nutrition 0.000 claims description 3
- 239000011647 vitamin D3 Substances 0.000 claims description 3
- 229940021056 vitamin d3 Drugs 0.000 claims description 3
- 230000036642 wellbeing Effects 0.000 claims description 3
- LGQKSQQRKHFMLI-SJYYZXOBSA-N (2s,3r,4s,5r)-2-[(3r,4r,5r,6r)-4,5,6-trihydroxyoxan-3-yl]oxyoxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)OC1 LGQKSQQRKHFMLI-SJYYZXOBSA-N 0.000 claims description 2
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 claims description 2
- JCSJTDYCNQHPRJ-UHFFFAOYSA-N 20-hydroxyecdysone 2,3-acetonide Natural products OC1C(O)C(O)COC1OC1C(O)C(O)C(OC2C(C(O)C(O)OC2)O)OC1 JCSJTDYCNQHPRJ-UHFFFAOYSA-N 0.000 claims description 2
- LGQKSQQRKHFMLI-UHFFFAOYSA-N 4-O-beta-D-xylopyranosyl-beta-D-xylopyranose Natural products OC1C(O)C(O)COC1OC1C(O)C(O)C(O)OC1 LGQKSQQRKHFMLI-UHFFFAOYSA-N 0.000 claims description 2
- 241001474374 Blennius Species 0.000 claims description 2
- 235000011331 Brassica Nutrition 0.000 claims description 2
- 241000219198 Brassica Species 0.000 claims description 2
- 241000218236 Cannabis Species 0.000 claims description 2
- 244000025254 Cannabis sativa Species 0.000 claims description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims description 2
- SQNRKWHRVIAKLP-UHFFFAOYSA-N D-xylobiose Natural products O=CC(O)C(O)C(CO)OC1OCC(O)C(O)C1O SQNRKWHRVIAKLP-UHFFFAOYSA-N 0.000 claims description 2
- 241000195634 Dunaliella Species 0.000 claims description 2
- 241000194031 Enterococcus faecium Species 0.000 claims description 2
- 241001409295 Handroanthus impetiginosus Species 0.000 claims description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 2
- 244000199885 Lactobacillus bulgaricus Species 0.000 claims description 2
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 2
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 2
- 241000186869 Lactobacillus salivarius Species 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 claims description 2
- 244000294611 Punica granatum Species 0.000 claims description 2
- 235000014360 Punica granatum Nutrition 0.000 claims description 2
- 229930003779 Vitamin B12 Natural products 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- 229940011019 arthrospira platensis Drugs 0.000 claims description 2
- 235000019206 astragalus extract Nutrition 0.000 claims description 2
- JCSJTDYCNQHPRJ-FDVJSPBESA-N beta-D-Xylp-(1->4)-beta-D-Xylp-(1->4)-D-Xylp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)C(O)OC2)O)OC1 JCSJTDYCNQHPRJ-FDVJSPBESA-N 0.000 claims description 2
- 235000009120 camo Nutrition 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 235000005607 chanvre indien Nutrition 0.000 claims description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 2
- 235000020694 echinacea extract Nutrition 0.000 claims description 2
- 229940002508 ginger extract Drugs 0.000 claims description 2
- 235000020708 ginger extract Nutrition 0.000 claims description 2
- 229960002849 glucosamine sulfate Drugs 0.000 claims description 2
- 239000011487 hemp Substances 0.000 claims description 2
- 229940095066 hydroxytyrosol Drugs 0.000 claims description 2
- 235000003248 hydroxytyrosol Nutrition 0.000 claims description 2
- 229940033355 lauric acid Drugs 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 2
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 claims description 2
- 239000010667 rosehip oil Substances 0.000 claims description 2
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 235000019163 vitamin B12 Nutrition 0.000 claims description 2
- 239000011715 vitamin B12 Substances 0.000 claims description 2
- ABKNGTPZXRUSOI-UHFFFAOYSA-N xylotriose Natural products OCC(OC1OCC(OC2OCC(O)C(O)C2O)C(O)C1O)C(O)C(O)C=O ABKNGTPZXRUSOI-UHFFFAOYSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 2
- 241000086254 Arnica montana Species 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 230000003648 hair appearance Effects 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 230000009471 action Effects 0.000 description 26
- 239000004480 active ingredient Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- 230000002195 synergetic effect Effects 0.000 description 11
- 230000001580 bacterial effect Effects 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 7
- 235000013406 prebiotics Nutrition 0.000 description 7
- 230000003712 anti-aging effect Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 206010016256 fatigue Diseases 0.000 description 5
- 244000005706 microflora Species 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 101150113809 COQ10 gene Proteins 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 244000005709 gut microbiome Species 0.000 description 4
- 230000007124 immune defense Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000000087 stabilizing effect Effects 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 208000027244 Dysbiosis Diseases 0.000 description 3
- 244000119461 Garcinia xanthochymus Species 0.000 description 3
- 235000000885 Garcinia xanthochymus Nutrition 0.000 description 3
- IVYPNXXAYMYVSP-UHFFFAOYSA-N Indole-3-carbinol Natural products C1=CC=C2C(CO)=CNC2=C1 IVYPNXXAYMYVSP-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 230000007140 dysbiosis Effects 0.000 description 3
- 230000003659 hair regrowth Effects 0.000 description 3
- 235000002279 indole-3-carbinol Nutrition 0.000 description 3
- RUMVKBSXRDGBGO-UHFFFAOYSA-N indole-3-carbinol Chemical compound C1=CC=C[C]2C(CO)=CN=C21 RUMVKBSXRDGBGO-UHFFFAOYSA-N 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 235000019136 lipoic acid Nutrition 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 229960002663 thioctic acid Drugs 0.000 description 3
- 229940032991 zinc picolinate Drugs 0.000 description 3
- NHVUUBRKFZWXRN-UHFFFAOYSA-L zinc;pyridine-2-carboxylate Chemical compound C=1C=CC=NC=1C(=O)O[Zn]OC(=O)C1=CC=CC=N1 NHVUUBRKFZWXRN-UHFFFAOYSA-L 0.000 description 3
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 230000002407 ATP formation Effects 0.000 description 2
- 206010001488 Aggression Diseases 0.000 description 2
- 241000208983 Arnica Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 2
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 2
- 229920002079 Ellagic acid Polymers 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- 241000736262 Microbiota Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 2
- 229960002747 betacarotene Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229940117916 cinnamic aldehyde Drugs 0.000 description 2
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 2
- 235000016213 coffee Nutrition 0.000 description 2
- 235000013353 coffee beverage Nutrition 0.000 description 2
- 230000000536 complexating effect Effects 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229960002852 ellagic acid Drugs 0.000 description 2
- 235000004132 ellagic acid Nutrition 0.000 description 2
- 230000000855 fungicidal effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 229940084084 white mulberry extract Drugs 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- RJFAYQIBOAGBLC-UHFFFAOYSA-N 2-amino-4-methylselanyl-butanoic acid Chemical compound C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 108700006072 E coli can Proteins 0.000 description 1
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 description 1
- 241000893536 Epimedium Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010061182 Genitourinary tract infection Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 description 1
- TZJALUIVHRYQQB-XFDQAQKOSA-N Icariin Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(C/C=C(\C)/C)c3O2)cc1 TZJALUIVHRYQQB-XFDQAQKOSA-N 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241000287509 Piciformes Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003761 Vitamin B9 Natural products 0.000 description 1
- JVZHSOSUTPAVII-UHFFFAOYSA-N Xylotetraose Natural products OCC(OC1OCC(OC2OCC(OC3OCC(O)C(O)C3O)C(O)C2O)C(O)C1O)C(O)C(O)C=O JVZHSOSUTPAVII-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 229960001009 acetylcarnitine Drugs 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000009418 agronomic effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002715 bioenergetic effect Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000015116 cappuccino Nutrition 0.000 description 1
- 230000002425 cardiocirculatory effect Effects 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000012846 chilled/fresh pasta Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940046374 chromium picolinate Drugs 0.000 description 1
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- GNWVUSJJFONIKF-UHFFFAOYSA-L copper;pyridine-2-carboxylate Chemical compound [Cu+2].[O-]C(=O)C1=CC=CC=N1.[O-]C(=O)C1=CC=CC=N1 GNWVUSJJFONIKF-UHFFFAOYSA-L 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 235000020237 cranberry extract Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000001258 dyslipidemic effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000018905 epimedium Nutrition 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000002178 gastroprotective effect Effects 0.000 description 1
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 1
- 235000002780 gingerol Nutrition 0.000 description 1
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 150000008131 glucosides Chemical group 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 235000015092 herbal tea Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229940089491 hydroxycitric acid Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 description 1
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- XYLIUBFEJNAWSC-UHFFFAOYSA-K iron(3+);pyridine-2-carboxylate Chemical compound [Fe+3].[O-]C(=O)C1=CC=CC=N1.[O-]C(=O)C1=CC=CC=N1.[O-]C(=O)C1=CC=CC=N1 XYLIUBFEJNAWSC-UHFFFAOYSA-K 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 239000012978 lignocellulosic material Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 230000006677 mitochondrial metabolism Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000000361 pesticidal effect Effects 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-M picolinate Chemical compound [O-]C(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-M 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229940109529 pomegranate extract Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000012433 rusks Nutrition 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 235000014268 sports nutrition Nutrition 0.000 description 1
- 230000037078 sports performance Effects 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000003741 urothelium Anatomy 0.000 description 1
- 230000002666 vasoprotective effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019159 vitamin B9 Nutrition 0.000 description 1
- 239000011727 vitamin B9 Substances 0.000 description 1
- 102000009310 vitamin D receptors Human genes 0.000 description 1
- 108050000156 vitamin D receptors Proteins 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940033282 vitamin b6 2 mg Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
- KPTPSLHFVHXOBZ-BIKCPUHGSA-N xylotetraose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O[C@H]3[C@@H]([C@@H](O)C(O)OC3)O)OC2)O)OC1 KPTPSLHFVHXOBZ-BIKCPUHGSA-N 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L9/00—Puddings; Cream substitutes; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Saccharide Compounds (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Fodder In General (AREA)
Description
Titolo: "XOS derivati della pannocchia del mais per potenziare la biodisponibilità e la stabilità delle materie prime nella produzione dei nutraceutici” Title: "XOS derivatives of corn cob to enhance the bioavailability and stability of raw materials in the production of nutraceuticals"
DESCRIZIONE DESCRIPTION
Stato dell’arte State of the art
I numerosissimi preparati nutraceutici o integratori alimentari immessi sul mercato dalle numerose aziende produttrici o commerciali, pur avendo composizioni simili, manifestano un'efficacia molto diversa. The numerous nutraceutical preparations or food supplements placed on the market by numerous manufacturing or commercial companies, despite having similar compositions, show a very different efficacy.
Infatti, oltre agli aspetti del mero titolo formulativo del preparato, vi sono altri aspetti tecnici, non presi in considerazione dal formulatore, quale la reale biodisponibilità dei principi attivi e la percentuale di assimilazione da parte del nostro organismo. In fact, in addition to the aspects of the mere formulation title of the preparation, there are other technical aspects, not taken into consideration by the formulator, such as the real bioavailability of the active ingredients and the percentage of assimilation by our body.
Questi due parametri sono importantissimi per una giusta valutazione di un preparato nutraceutico, poiché numerose materie prime, in primis quelle di origine naturale, sono poco stabili in presenza di un pHacido, tipico dell’ambiente gastrico. These two parameters are very important for a correct evaluation of a nutraceutical preparation, since many raw materials, primarily those of natural origin, are not very stable in the presence of an acidic pH, typical of the gastric environment.
Riassunto Summary
Gli inventori della presente domanda di brevetto hanno trovato che gli xylo-oligosaccaridi caratterizzati da un particolare grado di polimerizzazione presentano sorprendenti e vantaggiose proprietà; in particolare, si tratta degli xylooligosaccaridi ottenuti dal tutolo della pannocchia del mais. The inventors of the present patent application have found that the xylo-oligosaccharides characterized by a particular degree of polymerization have surprising and advantageous properties; in particular, these are xylooligosaccharides obtained from the cob of the corn cob.
Grazie a tali caratteristiche, possono quindi essere impiegati per ottenere prodotti dalle caratteristiche superiori. Thanks to these characteristics, they can therefore be used to obtain products with superior characteristics.
Oggetto dell’invenzione Object of the invention
Un primo oggetto della presente invenzione, pertanto, è rappresentato da una preparazione a base di xylo-oligosaccaridi. A first object of the present invention, therefore, is represented by a preparation based on xylo-oligosaccharides.
In un secondo oggetto sono descritte le applicazioni della preparazione dell’invenzione per la produzione di alimenti, alimenti funzionali, bevande, preparazioni farmaceutiche ad uso umano ed animale, integratori, ricostituenti, cosmetici, formulazioni agrochimiche. A second object describes the applications of the preparation of the invention for the production of foods, functional foods, beverages, pharmaceutical preparations for human and animal use, supplements, tonic, cosmetics, agrochemical formulations.
Descrizione dettagliata dell’invenzione Detailed description of the invention
Secondo un primo oggetto dell’invenzione sono descritte preparazioni a base di xylo-oligosaccaridi. Gli xylo-oligosaccaridi (XOS) sono una famiglia di polisaccaridi funzionali formati da catene glucosidiche di 2-7 molecole di xylano: According to a first object of the invention, preparations based on xylo-oligosaccharides are described. Xylo-oligosaccharides (XOS) are a family of functional polysaccharides formed by glucoside chains of 2-7 molecules of xylan:
In un aspetto particolare dell’invenzione, tali xylo-oligosaccaridi sono ottenuti da pannocchie del mais (Zea Mays) e, ancora più preferibilmente, dal tutolo della pannocchia. In a particular aspect of the invention, these xylo-oligosaccharides are obtained from corn cobs (Zea Mays) and, even more preferably, from the cob of the cob.
A tale scopo, il tutolo della pannocchia del mais (parte inutilizzata della stessa) è sottoposto ad una idrolisi acida mediante l’impiego di acido L-ascorbico in ragione dell’1-1,5%, in presenza di xilanasi. For this purpose, the cob of the corn cob (unused part of the same) is subjected to acid hydrolysis through the use of L-ascorbic acid in the ratio of 1-1.5%, in the presence of xylanase.
Secondo un aspetto preferito, gli xylooligosaccaridi impiegati per la preparazione delle formulazioni dell’invenzione sono caratterizzati da un grado di polimerizzazione inferiore a 6 e, ancora più preferibilmente, compreso fra 2 e 4 (xilobiosio (DP= 2), xilotriosio (DP= 3), xilotetraosio (DP= 4). According to a preferred aspect, the xylooligosaccharides used for the preparation of the formulations of the invention are characterized by a degree of polymerization lower than 6 and, even more preferably, between 2 and 4 (xylobiose (DP = 2), xylotriose (DP = 3 ), xylotetraose (DP = 4).
In un aspetto della presente invenzione, le preparazioni di xylo-oligosaccaridi sopra descritte possono essere impiegate in combinazione con uno o più principi attivi. In one aspect of the present invention, the xylo-oligosaccharide preparations described above can be used in combination with one or more active ingredients.
Tali principi attivi possono essere scelti nel gruppo che comprende: These active ingredients can be chosen from the group which includes:
- sali minerali, elementi, microelementi, eventualmente in forma organica, come ad esempio: selenio (ad esempio in forma di selenio metionina), zinco (ad esempio, zincopicolinato), cromo (ad esempio, cromopicolinato); - mineral salts, elements, microelements, possibly in organic form, such as for example: selenium (for example in the form of selenium methionine), zinc (for example, zincopicolinate), chromium (for example, chromopicolinate);
- vitamine, come ad esempio: vitamina B12, acido folico, biotina, vitamina D3; - vitamins, such as: vitamin B12, folic acid, biotin, vitamin D3;
- proteine ed amminoacidi, come ad esempio: L-citrullina, collagene, estratto di proteine (ad esempio, della soia); - proteins and amino acids, such as: L-citrulline, collagen, protein extract (for example, from soy);
- amminosaccaridi, come ad esempio: glucosammina solfato, condroitinsolfato, acido ialuronico; - aminosaccharides, such as: glucosamine sulfate, chondroitin sulfate, hyaluronic acid;
- antiossidanti, come ad esempio: polidatina, resveratrolo, licopene, idrossitirosoloe Nicotinamide adenin dinucleotide (NAD); - antioxidants, such as: polydatin, resveratrol, lycopene, hydroxytyrosol and Nicotinamide adenine dinucleotide (NAD);
- estratti vegetali e di alghe (anche comprendenti uno o più dei composti sopra indicati), come ad esempio: Serenoa repens (ad esempio, e.s. 30% acidi grassi), melograno (ad esempio, e.s. 20%acido ellagico), mirtillo nero (ad esempio, e.s. 36% antocianosidi), quercetina (ad esempio, al 95%), brassica (ad esempio, e.s. 99% indol-3-carbinolo), mirtillo rosso americano (cranberry fruit extract), estratto di ibisco, Butea superba, Epidemium(e.s.), spirulina (Arthrospira platensis), Garcinia cambogia, cannella, estratto di ortica, canapa (Cannabis), estratto di astragalo, estratto di echinacea, estratto di Tabebuia impetiginosa, olio di Rosa mosqueta, estratto di salvia, estratto di alga dunaliella (betacarotene 14%), rutina, estratto di zenzero, baheda, olio di amla, brahmi, bhringraj, shika kai, kapoor, olio di arnica; - plant and algae extracts (also including one or more of the compounds indicated above), such as: Serenoa repens (for example, e.s. 30% fatty acids), pomegranate (for example, e.s. 20% ellagic acid), bilberry ( e.g. 36% anthocyanosides), quercetin (e.g. 95%), brassica (e.g. 99% indole-3-carbinol), cranberry (cranberry fruit extract), hibiscus extract, Butea superba, Epidemium (e.g.), spirulina (Arthrospira platensis), Garcinia cambogia, cinnamon, nettle extract, hemp (Cannabis), astragalus extract, echinacea extract, Tabebuia impetiginosa extract, Rose hip oil, sage extract, seaweed extract dunaliella (beta-carotene 14%), rutin, ginger extract, baheda, amla oil, brahmi, bhringraj, shika kai, kapoor, arnica oil;
- altri composti scelti nel gruppo che comprende: metilsulfonilmetano, acido caprilico, acido laurico, oleuropina, farina fossile di diatomee; - other compounds selected from the group which includes: methylsulfonylmethane, caprylic acid, lauric acid, oleuropine, diatomaceous earth;
- preparazione microbiche comprendenti, adesempio: L. rhamnosus, L. acidophilus, L. plantarum, L. paracasei, L. salivarius, L. bulgaricus, Enterococcus faecium, etc. - microbial preparation including, for example: L. rhamnosus, L. acidophilus, L. plantarum, L. paracasei, L. salivarius, L. bulgaricus, Enterococcus faecium, etc.
Per le applicazioni in campo agronomico, le preparazioni dell’invenzione possono essere combinate conunoopiù dei composti scelti fra: ferro, magnesio, zinco, manganese, rame (nella forma di sali, ad esempio, sale solfato), urea. For applications in the agronomic field, the preparations of the invention can be combined with one or more of the compounds selected from: iron, magnesium, zinc, manganese, copper (in the form of salts, for example, sulphate salt), urea.
Le applicazioni di una preparazione secondo la presente invenzione sono molteplici e comprendono: - alimenti ed alimenti funzionali, come ad esempio: prodotti da forno (pane, grissini, cracker, fette biscottate, biscotti, preparati per pasta per la pizza), pasta fresca o secca, prodotti caseari (formaggio, yogurt, ricotta, mozzarella), latticini (preparazioni a base di panna), preparazioni per vegetariani o vegani in sostituzione della carne, salse, creme, sughi, budini, etc; The applications of a preparation according to the present invention are many and include: - functional foods and foods, such as: baked goods (bread, breadsticks, crackers, rusks, biscuits, preparations for pizza dough), fresh pasta or dry, dairy products (cheese, yogurt, ricotta, mozzarella), dairy products (cream-based preparations), preparations for vegetarians or vegans to replace meat, sauces, creams, gravies, puddings, etc;
- bevande e bevande funzionali, come ad esempio: succhi di frutta, caffè, preparati per bevande (caffè, cappuccino, bevande al ginseng, cioccolata, tisane, etc), latti vegetali o preparazioni a base di latte, preparazioni per brodo, reintegratori di sali minerali (ad esempio, per sportivi), birra, vino, acque minerali; - functional drinks and beverages, such as: fruit juices, coffee, beverage preparations (coffee, cappuccino, ginseng drinks, chocolate, herbal teas, etc.), vegetable milks or milk-based preparations, broth preparations, mineral salts (for example, for sportsmen), beer, wine, mineral waters;
- preparazioni farmaceutiche, integratori, ricostituenti; - pharmaceutical preparations, supplements, tonic;
- cosmetici, ad esempio: per il viso, per il corpo, per i capelli. - cosmetics, for example: for the face, for the body, for the hair.
In aggiunta a quanto sopra descritto, le preparazioni della presente invenzione possono trovare applicazione anche in campo agrochimico, per la preparazione, ad esempio, di formulazioni fertilizzanti (anche per applicazione fogliare) e biostimolanti. In addition to what has been described above, the preparations of the present invention can also find application in the agrochemical field, for the preparation, for example, of fertilizer formulations (also for foliar application) and biostimulants.
Con il termine “funzionale” si fa riferimento al fattochegli alimenti elebevande ottenute impiegando le preparazioni dell’invenzione sono specialmente adatte per soggetti in condizioni particolari, come: sportivi, anziani, persone soggette a stress o a stanchezza, obesi o in sovrappeso, insulinoresistenti, dislipidemici, persone soggette ad infezioni del tratto genito-urinario etc. The term "functional" refers to the fact that the foods and beverages obtained using the preparations of the invention are especially suitable for subjects in particular conditions, such as: sportspeople, the elderly, people subject to stress or fatigue, obese or overweight, insulin-resistant, dyslipidemic , people prone to genitourinary tract infections etc.
In ogni caso, le formulazioni comprendenti le preparazioni dell’invenzione, hanno sorprendentemente dimostrato di poter essere impiegate per uno o più dei seguenti scopi: In any case, the formulations comprising the preparations of the invention have surprisingly shown that they can be used for one or more of the following purposes:
- controllo della glicemia e del livello dell’insulina, - control of blood sugar and insulin level,
- attività anti-infiammatoria sistemica e/olocale, ad esempio nel caso di prostatiti, cistiti, dermatiti etc, - systemic and / or local anti-inflammatory activity, for example in the case of prostatitis, cystitis, dermatitis, etc.
- trattamento della disfunzione erettile, - antiossidante, - treatment of erectile dysfunction, - antioxidant,
- potenziamento del sistema immunitario, - strengthening of the immune system,
- attività dimagrante e/o per il controllo del peso corporeo, - slimming activity and / or for weight control,
- attività drenante e/o anti-cellulite, - disintossicante, - per combattere la caduta dei capelli, per favorirne la crescita e migliorarne l’aspetto, per ritardarne l’ingrigimento, per combattere la forfora, - per il benessere della pelle e delle unghie, - per i dolori articolari; - draining and / or anti-cellulite activity, - detoxifying, - to combat hair loss, to promote hair growth and improve its appearance, to delay graying, to combat dandruff, - for the well-being of the skin and nails, - for joint pain;
- attività antibatterica e antimicotica (ad esempio, contro Candida). - antibacterial and antifungal activity (for example, against Candida).
- per favorire il metabolismo energetico della cellula; - to promote the energy metabolism of the cell;
- per la disfunzione mitocondriale. - for mitochondrial dysfunction.
La presente invenzione verrà più dettagliatamente descritta nei seguenti esempi non limitativi di formulazioni. The present invention will be described in more detail in the following non-limiting examples of formulations.
ESEMPIO1 EXAMPLE 1
CONTROLLO CURVA GLICEMICA E INSULINEMICA GLYCEMIC AND INSULINEMIC CURVE CONTROL
i à i à
E’ stato sorprendentemente trovato come tra gli XOS e l’estratto di gelso bianco si crei un’azione sinergica nell’inibizione del picchio insulinico. Tale meccanismo, a breve termine, sembra derivare dall’azione ipoglicemizzante del gelso bianco. Alungo termine sembra derivare dagli XOS responsabili di un rilascio graduale degli zuccheri assunti durante i pasti e di una modulazione della microflora batterica coinvolta nei processi di digestione ed assorbimento degli zuccheri. Inoltre, l’effetto complessante della fibra genera una possibile sinergia tra i gruppi ossidrilici con il principio attivo dell’estratto di gelso bianco (1-deossi-noirimicina). L’acido folico manifesta un’azione carrier nei confronti della vitamina D3, cromo e zinco. It was surprisingly found that between the XOS and the white mulberry extract a synergistic action is created in the inhibition of the insulin woodpecker. This mechanism, in the short term, seems to derive from the hypoglycemic action of the white mulberry. In the long term it seems to derive from the XOS responsible for a gradual release of the sugars taken during meals and for a modulation of the bacterial microflora involved in the digestion and absorption processes of sugars. In addition, the complexing effect of the fiber generates a possible synergy between the hydroxyl groups with the active ingredient of the white mulberry extract (1-deoxy-noirimycin). Folic acid manifests a carrier action against vitamin D3, chromium and zinc.
La formulazione dell’Esempio andrà preferibilmente assunta tre volte al giorno. The formulation of the Example should preferably be taken three times a day.
ESEMPIO2 EXAMPLE 2
PROSTATITI PROSTATITES
Si manifesta un’azione sinergica tra gli XOS e l’estratto di Serenoa repens, l’acido ellagico dell’estratto di melograno, gli antocianosidi del mirtillo nero, la quercetina e l’indol-3-carbinolo, nonché un’azione carrier dell’acido folico nei confronti dello zinco, del licopene e dell’indol-3-carbinolo. Si nota un’azione sinergica tra zinco e licopene. There is a synergistic action between XOS and the extract of Serenoa repens, the ellagic acid of the pomegranate extract, the anthocyanosides of the bilberry, the quercetin and the indole-3-carbinol, as well as a carrier action of the folic acid against zinc, lycopene and indole-3-carbinol. There is a synergistic action between zinc and lycopene.
L’associazione fra Serenoa repens, licopene e selenio porta a una notevole riduzione della infiammazione della prostata, inibendo l’espressione di proteine coinvolte nel processo infiammatorio. Si nota un particolare effetto antiossidante ed antinfiammatorio prodotto proprio dal sinergismo di azione dei principi attivi con gli XOS. The association between Serenoa repens, lycopene and selenium leads to a significant reduction in inflammation of the prostate, inhibiting the expression of proteins involved in the inflammatory process. There is a particular antioxidant and anti-inflammatory effect produced precisely by the synergistic action of the active ingredients with XOS.
La formulazione dell’Esempio andrà preferibilmente assunta due volte al giorno. The formulation of the Example should preferably be taken twice a day.
ESEMPIO3 EXAMPLE 3
CISTITI CYSTITIS
i à i à
Si nota un’attività sinergica fra l’estratto di mirtillo rosso e gli XOS, tale da indurre la proliferazione di Lactobacillus rhamnosus in grado di ridurre l’aggressività delle infezioni urinarie causate da E. coli su due fronti: in primo luogo evita che E. coli si possa agganciare alle pareti delle vie urinarie e, in secondo luogo, attiva le difese immunitarie, perché possano combattere l’infezione più rapidamente. Si nota un’azione sinergica tra gli XOS e gli antociani dell’estratto di mirtillo rosso ed ibisco, nonché un’azione prebiotica degli XOS nei confronti della microflora intestinale (bifidobatteri e lattobacilli) a scapito dei gram-negativi. Tale formulazione, grazie alla capacità di ristabilire l’equilibrio intestinale, svolge un effetto combinato sui disordini enterici e genitourinari. There is a synergistic activity between cranberry extract and XOS, such as to induce the proliferation of Lactobacillus rhamnosus capable of reducing the aggressiveness of urinary infections caused by E. coli on two fronts: firstly it prevents E coli can attach itself to the walls of the urinary tract and, secondly, activates the immune defenses, so that they can fight the infection more quickly. There is a synergistic action between the XOS and the anthocyanins of the cranberry and hibiscus extract, as well as a prebiotic action of the XOS against the intestinal microflora (bifidobacteria and lactobacilli) to the detriment of the gram-negative ones. This formulation, thanks to the ability to restore intestinal balance, has a combined effect on enteric and genitourinary disorders.
La formulazione dell’Esempio andrà preferibilmente assunta due volte al giorno. The formulation of the Example should preferably be taken twice a day.
ESEMPIO4 EXAMPLE 4
DISFUNZIONE ERETTILE ERECTILE DYSFUNCTION
Si nota una azione carrier degli XOS nei confronti dei fitosteroli presenti nell’estratto di Butea superba. Tale interazione permette di ottenere una elevata biodisponibilità dei principi attivi tramite un duplice meccanismo, cioè: un’azione carrier e una maggiore biodisponibilità per mezzo della biomodulazione della microflora batterica utile e un’azione coadiuvante degli XOS nei confronti dell’icariina, il principio attivo dell’epimedium, con azione vasoprotettiva e vasodilatatrice. Gli XOS migliorano l’azione vasodilatatrice della L-citrullina, agendo in maniera positiva sul microbiota. La formulazione dell’Esempio andrà preferibilmente assunta tre volte al giorno. There is a carrier action of XOS against the phytosterols present in the Butea superba extract. This interaction allows to obtain a high bioavailability of the active ingredients through a double mechanism, that is: a carrier action and a greater bioavailability by means of the biomodulation of the useful bacterial microflora and an adjuvant action of XOS against icariin, the active ingredient of the epimedium, with vasoprotective and vasodilating action. XOS improve the vasodilating action of L-citrulline, acting positively on the microbiota. The formulation of the Example should preferably be taken three times a day.
ESEMPIO5 EXAMPLE 5
POTENZIAMENTO SISTEMA IMMUNITARIO, AZIONE ENHANCEMENT IMMUNE SYSTEM, ACTION
ANTIOSSIDANTE ED ANTINFIAMMATORIA ANTIOXIDANT AND ANTI-INFLAMMATORY
Gli XOS manifestano un’azione veicolante nei confronti di tutte le sostanze contenute nella formulazione, in modo particolare nei confronti della polidatina, uno stilbene altamente antiossidante ed altamente idrosolubile e biodisponibile rispetto ad altre molecole quali, ad esempio, il resveratrolo. Inoltre, manifesta un’azione antibatterica ed antivirale, e potenzia le vie di segnalazione del recettore della vitamina D3 coinvolto nei meccanismi antiproliferativi ed immunoregolatori. Il preparato manifesta un’azione protettiva anche a livello cardiovascolare, inibendo l’ossidazione del colesterolo LDL. L’azione sinergica antiossidante ed antiinfiammatoria di tali molecole sembrerebbe inoltre favorire i meccanismi fisiologici legati al dimagrimento, alla resistenza all’insulina e, quindi, anche al diabete e all’obesità. XOS show a carrier action towards all the substances contained in the formulation, in particular towards polydatin, a highly antioxidant and highly water-soluble and bioavailable stilbene compared to other molecules such as, for example, resveratrol. In addition, it exhibits an antibacterial and antiviral action, and enhances the signaling pathways of the vitamin D3 receptor involved in antiproliferative and immunoregulatory mechanisms. The preparation also has a protective action at the cardiovascular level, inhibiting the oxidation of LDL cholesterol. The synergistic antioxidant and anti-inflammatory action of these molecules would also seem to favor the physiological mechanisms related to weight loss, insulin resistance and, therefore, also to diabetes and obesity.
La formulazione dell’Esempio andrà preferibilmente assunta due volte al giorno. The formulation of the Example should preferably be taken twice a day.
ESEMPIO 6 EXAMPLE 6
PERDITA DI PESO E DISINTOSSICAZIONE DELL'ORGANISMO WEIGHT LOSS AND DETOXIFICATION OF THE BODY
Si nota un’azione complessante e veicolante degli XOS nei confronti del principio attivo della Garcinia cambogia (acido idrossicitrico) la quale, in sinergia con il cromo picolinato, agisce sul metabolismo degli zuccheri. Si manifesta, inoltre, un’azione lassativa secondaria per l’eliminazione del grasso. Vi è una particolare sinergia tra la garcinia e la spirulina, con effetto sull’accelerazione del metabolismo unita ad un’azione brucia-grassi. There is a complexing and carrying action of XOS against the active ingredient of Garcinia cambogia (hydroxycitric acid) which, in synergy with chromium picolinate, acts on the metabolism of sugars. There is also a secondary laxative action for the elimination of fat. There is a particular synergy between garcinia and spirulina, with an effect on accelerating the metabolism combined with a fat-burning action.
La formulazione dell’Esempio andrà preferibilmente assunta in due compresse per tre volte al giorno, preferibilmente mezz’ora prima dei pasti (mattina, mezzogiorno e sera). The formulation of the Example should preferably be taken in two tablets three times a day, preferably half an hour before meals (morning, noon and evening).
ESEMPIO7 EXAMPLE 7
PER RINFORZARE CAPELLI E PELLE TO STRENGTHEN HAIR AND SKIN
Gli XOS potenziano la biodisponibilità e l’assimilabilità dei componenti presenti nella formulazione, favorendo l’azione ricostituente e rigenerante del capello e dalla cute. Inoltre, potenzianola sinergia tra biotinae zincoper favorire la ricrescita del capello. La cannella favorisce e stimola la circolazione sanguigna, aiutando la ricrescita naturale dei capelli. La proprietà antimicrobica esercitata dalla cannella viene incrementata dall’attività del selenio e degli XOS. L’utilizzo di tale integratore ha mostrato sorprendenti risultati per il trattamento della pelle secca, contro le rughe, e più in generale come antinvecchiamento. Tali sorprendenti risultati sono imputabili all’azione prebiotica degli XOS a livello intestinale, che contrasta stati infiammatori cronici collegati all’insorgenza di patologie dermatologiche direttamente collegate quali, ad esempio: psoriasi, eczemi, etc. XOS enhance the bioavailability and assimilability of the components present in the formulation, favoring the restorative and regenerating action of the hair and skin. Furthermore, they enhance the synergy between biotin and zinc to promote hair regrowth. Cinnamon promotes and stimulates blood circulation, helping natural hair regrowth. The antimicrobial property exerted by cinnamon is increased by the activity of selenium and XOS. The use of this supplement has shown surprising results for the treatment of dry skin, against wrinkles, and more generally as an anti-aging. These surprising results are attributable to the prebiotic action of XOS in the intestine, which counteracts chronic inflammatory states linked to the onset of directly related dermatological diseases such as, for example: psoriasis, eczema, etc.
Tale azione viene potenziata, come precedentemente affermato, dall’effetto stimolante ed antiossidante dell’aldeide cinnamica e del selenio. This action is enhanced, as previously stated, by the stimulating and antioxidant effect of cinnamic aldehyde and selenium.
La formulazione dell’Esempio andrà preferibilmente assunta due volte al giorno. The formulation of the Example should preferably be taken twice a day.
ESEMPIO8 EXAMPLE 8
DOLORI ARTICOLARI – ARTROSI JOINT PAIN - ARTHROSIS
Gli XOS svolgono una duplice azione di carrier molecolari favorendo il trasporto ed il rilascio delle molecole adattività antiinfiammatoria e ricostituente le articolazioni e, allo stesso tempo, determinando un miglioramento dello stato infiammatorio intestinale, determina un miglioramento delle patologie infiammatorie correlate ad artrite reumatoide ed artrosi. XOS carry out a dual action of molecular carriers favoring the transport and release of anti-inflammatory and reconstituting molecules in the joints and, at the same time, by determining an improvement in the intestinal inflammatory state, it determines an improvement of inflammatory pathologies related to rheumatoid arthritis and arthrosis.
Gli XOS permettono di migliorare la biodisponibilità dei principi attivi contenuti nella formulazione, favoriscono la riparazione e la sintesi della cartilagine. Si evidenzia una spiccata azione sinergica antinfiammatoria sulle articolazioni tra XOS, selenio e condroitinsolfato. Tale azione viene anche indotta dalla presenza degli XOS che, svolgendo un’azione positiva sugli stati di disbiosi intestinale, influenzano la severità dei dolori articolari modulando i livelli di citochine ed autoanticorpi. The XOS allow to improve the bioavailability of the active ingredients contained in the formulation, favor the repair and synthesis of cartilage. There is a marked synergistic anti-inflammatory action on the joints between XOS, selenium and chondroitin sulfate. This action is also induced by the presence of XOS which, by carrying out a positive action on intestinal dysbiosis states, influence the severity of joint pain by modulating the levels of cytokines and autoantibodies.
La formulazione dell’Esempio andrà preferibilmente assunta tre volte al giorno. The formulation of the Example should preferably be taken three times a day.
ESEMPIO9 EXAMPLE 9
AZIONE ANTICELLULITE E ANTINFIAMMATORIA: ANTI-CELLULITE AND ANTI-INFLAMMATORY ACTION:
Gli XOS manifestano un’eccezionale azione veicolante nei confronti dell’acido ialuronico e del collagene, la cui assimilazione viene favorita dal silicio organico. L’estratto di ortica e gli XOS favoriscono l’assorbimento del silicio organico. Il formulato manifesta un’eccezionale azione anti-age (sulle rughe) e rimpolpante, grazie ad un miglioramento della elasticità della pelle ed un effetto ricostituente. XOS show an exceptional carrier action against hyaluronic acid and collagen, whose assimilation is favored by organic silicon. Nettle extract and XOS promote the absorption of organic silicon. The formulation has an exceptional anti-aging (on wrinkles) and plumping action, thanks to an improvement in skin elasticity and a restorative effect.
ESEMPIO10 EXAMPLE 10
CANNABIS PER USOMEDICALE CANNABIS FOR MEDICAL USE
Gli XOS manifestano un’importante azione gastroprotettiva, oltre a migliorarne la biodisponibilità dei principi attivi. XOS show an important gastroprotective action, as well as improving the bioavailability of the active ingredients.
ESEMPIO11 EXAMPLE 11
OVULI VAGINALI VAGINAL OVULES
L’azione prebiotica degli XOS utilizzati in loco, agisce sinergicamente con l’attività antibatterica selettiva dell’astragalo e dell’estratto di karkadè e conl’attività fungicida (inparticolare nei confronti della candida) dell’acido caprilico, in modo da riequilibrare la microflora vaginale. The prebiotic action of the XOS used on site acts synergistically with the selective antibacterial activity of astragalus and karkadè extract and with the fungicidal activity (in particular against candida) of caprylic acid, in order to rebalance the microflora vaginal.
L’efficacia di tale formulazione fitoterapica, è sostenuta dalla sinergica stimolazione immunitaria generale e locale, che contrasta l’infiammazione e inibisce la penetrazione dei microrganismi patogeni nelle cellule dell’urotelio. The effectiveness of this phytotherapeutic formulation is supported by the synergistic general and local immune stimulation, which counteracts inflammation and inhibits the penetration of pathogenic microorganisms into the urothelium cells.
ESEMPIO12 EXAMPLE 12
CREMA VISO FACE CREAM
E’ stato osservato come gli XOS, interagendo sinergicamente con la polidatina, ne favoriscono l’azione immunostimolante a livello cutaneo. La polidatina e la rutina svolgono un’azione anti-età ed antiossidante e, penetrando in profondità, agiscono anche a livello intracellulare. L’estratto di salvia presenta attività antibatteriche, antifungine, virusstatiche, seboregolatrici ed astringenti, viene utilizzato per il trattamento delle pelli grasse, impure e contendenza acneica. Il β-carotene, presente nella microalga (fino al 14% del suo peso secco) quale precursore della vitamina A(retinolo), esercita una spiccata azione antiossidante per le nostre cellule ed un ruolo nell’equilibrio fisiologico del nostro organismo attraverso il potenziamento delle difese immunitarie dovute ai linfociti T e B. It has been observed that XOS, interacting synergistically with polydatin, favor its immunostimulating action on the skin. Polydatin and rutin have an anti-aging and antioxidant action and, penetrating deeply, they also act at the intracellular level. Sage extract has antibacterial, antifungal, virus-static, sebum-regulating and astringent activities, it is used for the treatment of oily, impure and acne-prone skin. The β-carotene, present in the microalgae (up to 14% of its dry weight) as a precursor of vitamin A (retinol), exerts a strong antioxidant action for our cells and a role in the physiological balance of our organism through the strengthening of immune defenses due to T and B lymphocytes
Anche in questo caso la sorprendente attività anti-age viene data dalla sinergia di azione tra gli XOS, che modulando i parametri intestinali, favoriscono il benessere della pelle e gli effetti lenitivi e antiossidanti degli altri costituenti. Also in this case the surprising anti-aging activity is given by the synergy of action between the XOS, which by modulating the intestinal parameters, favor the well-being of the skin and the soothing and antioxidant effects of the other constituents.
Il meccanismo di azione risulta essere duplice, combattendo l’invecchiamento dall’interno ed apportando nutrienti a livello topico. The mechanism of action is twofold, fighting aging from the inside and providing topical nutrients.
ESEMPIO13 EXAMPLE 13
INTEGRATORE STABILIZZANTE L’INSULINA INSULIN STABILIZING SUPPLEMENT
composto quantità XOS 500 mg ESTRATTODI OLIODI OLIVA (20%OLEUROPINA) compound quantity XOS 500 mg OLIVE OIL EXTRACT (20% OLEUROPINE)
CROMOPICOLINATO 120 mcg ESTRATTOZENZERO20%(GINGEROLI) CHROMOPICOLINATE 120 mcg ZINGER EXTRACT 20% (GINGEROLI)
CANNELLA (ALDEIDE CINNAMICA) 100 mg L’effetto stabilizzante sull’insulina si manifesta mediante una duplice azione sinergica: sul breve termine: oleuropina, gingerolo ed aldeide cinnamica regolarizzano la secrezione e la sensibilità insulinica; gli XOS, invece, modulano positivamente la microflora intestinale batterica che influenza i parametri metabolici, colesterolo, glicemia, e la pressione arteriosa. Gli XOS, inoltre, determinano un rilascio graduale degli zuccheri a livello intestinale determinando ungraduale aumento del picco insulinico. Tale azione stabilizzante, mostra effetti positivi nella prevenzione e nel miglioramento dei quadri metabolici di diabete di tipo 2, insulino-resistenza e sindrome metabolica. CINNAMON (KYNAMIC ALDEHYDE) 100 mg The stabilizing effect on insulin is manifested by a double synergistic action: in the short term: oleuropin, gingerol and cinnamic aldehyde regulate insulin secretion and sensitivity; the XOS, on the other hand, positively modulate the bacterial intestinal microflora which influences metabolic parameters, cholesterol, glycaemia, and blood pressure. Furthermore, XOS determine a gradual release of sugars in the intestine, causing a gradual increase in the insulin peak. This stabilizing action shows positive effects in the prevention and improvement of the metabolic conditions of type 2 diabetes, insulin resistance and metabolic syndrome.
La formulazione dell’Esempio andrà preferibilmente assunta due volte al giorno. The formulation of the Example should preferably be taken twice a day.
ESEMPIO14 EXAMPLE 14
LOZIONE ANTICADUTA PER CAPELLI HAIR LOSS LOTION
composto composed
XOS XOS
BAHEDA BAHEDA
OLIODI AMLA AMLA OILS
BRAHMI BRAHMI
BHRINGRAJ BHRINGRAJ
SHIKA KAI SHIKA KAI
KAPOOR KAPOOR
OLEUROPINA OLEUROPINE
OLIODI ARNICA ARNICA OILS
Il sinergismo degli XOS con gli altri componenti mira al riequilibrio della microflora batterica del cuoio capelluto, all’azione antisettica e battericida selettiva ed alla stimolazione della ricrescita del capello. L’utilità si estende, quindi, al trattamento della forfora, dermatite seborroica, ma anche della alopecia cicatriziale da lichen plano pilare. E’ stato notatocome gli XOS potenziano gli effetti dei principi attivi delle piante ayurvediche della formulazione favorendone sia un migliore assorbimento, sia creando un substrato adatto alla proliferazione della microflora benefica a livello topico. The synergy of XOS with the other components aims at rebalancing the bacterial microflora of the scalp, at the selective antiseptic and bactericidal action and at stimulating hair regrowth. Its usefulness therefore extends to the treatment of dandruff, seborrheic dermatitis, but also of cicatricial alopecia due to lichen plano pilare. It has been noted that XOS enhance the effects of the active ingredients of the Ayurvedic plants in the formulation, promoting both better absorption and creating a substrate suitable for the proliferation of beneficial microflora at the topical level.
ESEMPIO 15 EXAMPLE 15
FORMULAZIONE BIOSTIMOLANTE PER L'AGRICOLTURA BIOSTIMULANT FORMULATION FOR AGRICULTURE
BIOLOGICA BIOLOGICAL
ESEMPIO 16 EXAMPLE 16
FORMULAZIONE FERTILIZZANTE FERTILIZER FORMULATION
La formulazione è preferibilmente impiegata per applicazione fogliare. The formulation is preferably used for foliar application.
ESEMPIO17 EXAMPLE 17
FORMULAZIONE PER USOANIMALE FORMULATION FOR ANIMAL USE
Indicato in caso di disbiosi causate da infezioni batteriche, virali, parassitosi, disturbi intestinali da alimentazione, infiammazioni croniche, squilibri causati dall’utilizzo di antibiotici, antinfiammatori, o da situazioni di stress. Indicated in cases of dysbiosis caused by bacterial, viral, parasitic infections, intestinal disorders from nutrition, chronic inflammation, imbalances caused by the use of antibiotics, anti-inflammatories, or stressful situations.
L’azione simbiontica di tale prodotto è potenziata dall’effetto antiparassitario della terra fossile di diatomee ed ha un triplice effetto: antibatterico, antivirale e fungicida grazie all’acido laurico, per un riequilibrio della microflora intestinale batterica. The symbiotic action of this product is enhanced by the pesticide effect of diatomaceous earth and has a triple effect: antibacterial, antiviral and fungicidal thanks to lauric acid, for a rebalancing of the bacterial intestinal microflora.
La formulazione dell’Esempio andrà preferibilmente assunta una volta al giorno. The formulation of the Example should preferably be taken once a day.
ESEMPIO18 EXAMPLE 18
FORMULAZIONE ANTI-AGE ANTI-AGE FORMULATION
composto quantità compound quantity
XOS 400 mg XOS 400 mg
NADH 15 mg NADH 15 mg
POLIDATINA 50 mg POLYDATIN 50 mg
La suddetta preparazione presenta una spiccata attività antiossidante ed anti-age. The aforementioned preparation has a marked antioxidant and anti-aging activity.
Grazie all’azione stabilizzante e carrier degli XOS, il NADH, coinvolto nel metabolismo energetico ed elemento chiave per la produzione di ATP, agisce rafforzando il sistema immunitario e protegge dai danni cellulari prodotti da radicali liberi. Gli XOS, inoltre, agiscono aumentando la già elevata stabilità e solubilità della polidatina inmododa poter svolgere al massimo la sua azione preventiva e curativa. Thanks to the stabilizing and carrier action of XOS, NADH, involved in energy metabolism and a key element in the production of ATP, acts by strengthening the immune system and protects against cell damage produced by free radicals. Furthermore, XOS act by increasing the already high stability and solubility of polydatin so that it can perform its preventive and curative action to the maximum.
La formulazione dell’Esempio andrà preferibilmente assunta tre volte al giorno. The formulation of the Example should preferably be taken three times a day.
ESEMPIO 19 EXAMPLE 19
FORMULAZIONE PER LA DISFUNZIONE MITOCONDRIALE FORMULATION FOR MITOCHONDRAL DYSFUNCTION
composto quantità compound quantity
XOS 300 mg XOS 300 mg
Lactobacillus 150 mg Lactobacillus 150 mg
spp spp
NADH 5 mg NADH 5 mg
COQ10 200 mg COQ10 200 mg
ACIDOα-LIPOICO 200 mg Α-LIPOIC ACID 200 mg
ACETIL-L- 250 mg ACETYL-L- 250 mg
CARNITINA PIRROLOCHINOLINA 20 mg Tale formulazione è stata messa a punto appositamente al fine di combattere stati di affaticamento cronico e stimolare il metabolismo mitocondriale. CARNITINE PIRROLOQUINOLINA 20 mg This formulation has been specially developed in order to combat chronic fatigue and stimulate mitochondrial metabolism.
La specifica formulazione simbiontica induce, tramite specifici meccanismi molecolari, l’attivazione del metabolismo energetico della cellula combattendo il senso di fatica cronica e l’astenia, tipici di stati patologici quali la fibromialgia. The specific symbiotic formulation induces, through specific molecular mechanisms, the activation of the cell's energy metabolism, fighting the sense of chronic fatigue and asthenia, typical of pathological states such as fibromyalgia.
Inoltre il NADH (coenzima che partecipa ai processi di produzione di energia cellulare) ed il COQ10 (cofattore antiossidante richiesto nella sintesi di ATP e nell’attività bioenergetica cellulare) agiscono in sinergia con l’acido α-lipoico, sostanza produttrice e ottimizzatrice di energia cellulare, che potenzia l’azione energetica ed antiossidante della formulazione. Furthermore, NADH (coenzyme that participates in cellular energy production processes) and COQ10 (antioxidant cofactor required in ATP synthesis and cellular bioenergetic activity) act in synergy with α-lipoic acid, a substance that produces and optimizes energy. cellular, which enhances the energy and antioxidant action of the formulation.
I risultati ottenuti dalla contemporanea assunzione di tali molecole, rese ancora più biodisponibili dagli XOS, dimostrano una prestazione migliore di tale formulazione rispetto ad una assunzione separata dei singoli componenti. The results obtained from the simultaneous intake of these molecules, made even more bioavailable by the XOS, demonstrate a better performance of this formulation compared to a separate intake of the individual components.
Tale formulazione, inoltre, ha un’azione importante sul miglioramento della performance sportiva grazie alla sinergia di N-acetil-carnitina, l’acidoα-lipoico ed il CoQ10. This formulation also has an important action on improving sports performance thanks to the synergy of N-acetyl-carnitine, α-lipoic acid and CoQ10.
Tale formulazione è indicata quindi, in modo particolare, per soggetti affetti da miopatie, fibromialgia, disfunzione mitocondriale, soggetti anziani con stanchezza cronica ed obesità e per gli atleti. This formulation is therefore particularly indicated for subjects suffering from myopathies, fibromyalgia, mitochondrial dysfunction, elderly subjects with chronic fatigue and obesity and for athletes.
La formulazione dell’Esempio andrà preferibilmente assunta tre volte al giorno. The formulation of the Example should preferably be taken three times a day.
Esempio 20 Example 20
FORMULAZIONE INDICATA PER LO STRESS OSSIDATIVO FORMULATION SUITABLE FOR OXIDATIVE STRESS
composto quantità compound quantity
XOS 500 mg SOD da carota 20 mg (come e.s.) licopene 50 mg Vit A 600 mcg Vit C 40 mg Vit E 10 mg Zinco 50 mg picolinato COQ10 50 mg XOS 500 mg SOD from carrot 20 mg (as d.e.) lycopene 50 mg Vit A 600 mcg Vit C 40 mg Vit E 10 mg Zinc 50 mg picolinate COQ10 50 mg
Tale formulazione è stata specificatamente progettata al fine di contrastare i danni e le patologie cronicodegenerative indotte dall’azione dei radicali liberi. Le attività prebiotiche, antiossidanti e stimolanti il metabolismo energetico di tale formulazione, sono il frutto di una sinergia di azione tra gli XOS e molecole antiossidanti quali vitamine A, C, E, il COQ10, la SOD, il licopene e lo zinco picolinato. This formulation was specifically designed in order to counteract damage and chronic degenerative diseases induced by the action of free radicals. The prebiotic, antioxidant and energy metabolism stimulating activities of this formulation are the result of a synergy of action between XOS and antioxidant molecules such as vitamins A, C, E, COQ10, SOD, lycopene and zinc picolinate.
È stata notata una azione sinergica tra XOS, zinco e licopene non altrimenti riproducibile singolarmente. Tale formulazione è particolarmente indicata per contrastare l’invecchiamento cellulare, patologie croniche quali disturbi cardio-circolatori, diabete, cancro e malattie neurodegenerative. A synergistic action has been noted between XOS, zinc and lycopene not otherwise reproducible individually. This formulation is particularly suitable for combating cellular aging, chronic diseases such as cardio-circulatory disorders, diabetes, cancer and neurodegenerative diseases.
Tali attività sembrano essere imputabili ancora una volta al duplice effetto degli XOS. These activities appear to be attributable once again to the dual effect of XOS.
All’azione carrier nei confronti delle molecole antiossidanti, si aggiunge la capacità di aumentarne la biodisponibilità e l’assimilazione da parte dell’organismo, per mezzo della modulazione della microflora intestinale batterica. Allo stesso tempo, le vitamine, cambiando lo stato redox intestinale, sono in grado di controllare le sotto-popolazioni del microbiota che rappresenta il principale target di tale formulazione per la prevenzione delle patologie mediate da stress ossidativo. To the carrier action against antioxidant molecules, is added the ability to increase their bioavailability and assimilation by the body, by modulating the bacterial intestinal microflora. At the same time, vitamins, by changing the intestinal redox state, are able to control the sub-populations of the microbiota which represents the main target of this formulation for the prevention of pathologies mediated by oxidative stress.
La formulazione dell’Esempio andrà preferibilmente assunta due volte al giorno. The formulation of the Example should preferably be taken twice a day.
ESEMPIO 21 EXAMPLE 21
FORMULAZIONE INDICATA PER LE ANEMIE FORMULATION SUITABLE FOR ANEMIA
composto quantità compound quantity
XOS 1 mg/die XOS 1 mg / day
FERROPICOLINATO 10 mg/die FERROPICOLINATE 10 mg / day
VITAMINA B12 3 µg/die VITAMIN B12 3 µg / day
VITAMINA B9 0,5 mg/die VITAMIN B9 0.5 mg / day
VITAMINA B6 2 mg/die VITAMIN B6 2 mg / day
Vit C 150 mg/die Vit C 150 mg / day
Vit E 60 mg/die Vit E 60 mg / day
RAME PICOLINATO 2 mg/die PICOLINATE COPPER 2 mg / day
Zinco picolinato 10 mg/die Zinc picolinate 10 mg / day
Tale formulazione agisce contrastando gli stati di disbiosi intestinale correlati a quadri anemici e sindromi mal assorbitive e rendendo il ferro altamente biodisponibile ed assimilabile, favorendo la normale formazione dei globuli rossi e dell’emoglobina, il trasporto dell’ossigeno e la riduzione di stanchezza ed affaticamento. This formulation acts by counteracting the states of intestinal dysbiosis related to anemic pictures and malabsorbing syndromes and making the iron highly bioavailable and assimilable, favoring the normal formation of red blood cells and hemoglobin, the transport of oxygen and the reduction of tiredness and fatigue. .
L’efficacia della formulazione è dovuta ad un duplice meccanismo prebiotico e carrier degli XOS che mostrano un significativo aumento dell’assimilazione del ferro picolinato in combinazione con la Vit C ed una aumentata azione carrier della Vit B9 nei confronti del rame e dello zinco picolinato. The effectiveness of the formulation is due to a dual prebiotic and carrier mechanism of XOS which show a significant increase in the assimilation of iron picolinate in combination with Vit C and an increased carrier action of Vit B9 against copper and zinc picolinate.
L’azione prebiotica degli XOS, unitamente all’apporto di micronutrienti e Vitamine, favoriscono il miglioramento dei parametri ematici in soggetti anemici. The prebiotic action of XOS, together with the supply of micronutrients and vitamins, favor the improvement of blood parameters in anemic subjects.
Tale formulazione è quindi indicata nei casi di scarso apporto di ferro con la dieta, di aumentato fabbisogno di tali nutrienti o nel caso di malassorbimento intestinale. This formulation is therefore indicated in cases of low iron intake with the diet, an increased need for these nutrients or in the case of intestinal malabsorption.
Dalla descrizione fornita della presente invenzione sono immediatamente evidenti i vantaggi offerti dalle preparazioni descritte. The advantages offered by the preparations described are immediately evident from the description provided of the present invention.
Come sopra descritto, la preparazione di xylooligosaccaridi della presente invenzione presenta proprietà sorprendenti ed inattese rispetto a preparazioni di altri polisaccaridi, come i fruttooligosaccaridi (FOS) e l’inulina. As described above, the preparation of xylooligosaccharides of the present invention has surprising and unexpected properties compared to preparations of other polysaccharides, such as fructooligosaccharides (FOS) and inulin.
Inoltre, il gruppo di xylo-oligosaccaridi caratterizzati da un grado di polimerizzazione fino a 6 e, più in particolare, compreso fra 2 e 4, hanno dimostrato proprietà ancora più sorprendenti. Furthermore, the group of xylo-oligosaccharides characterized by a degree of polymerization up to 6 and, more particularly, between 2 and 4, have shown even more surprising properties.
Ciò consente l’impiego di preparazioni dalle proprietà sorprendentemente vantaggiose da diversi punti di vista. This allows the use of preparations with surprisingly advantageous properties from different points of view.
Ad esempio, tali preparazioni sono molto stabili a pH acido, tipicamente quello gastrico. For example, such preparations are very stable at acid pH, typically gastric.
E’ stato anche notato come le preparazioni dell’invenzione possoessere impiegate come veicolanti per altri principi attivi, ad esempio rappresentati da vitamine (specialmente B1, B2, B6, B12, acido niacinico e acido folico), antiossidanti, proteine, sali minerali, migliorandone ampiamente l’attività e la biodisponibilità. It has also been noted how the preparations of the invention can be used as carriers for other active ingredients, for example represented by vitamins (especially B1, B2, B6, B12, niacinic acid and folic acid), antioxidants, proteins, mineral salts, improving them widely the activity and bioavailability.
Non deve essere dimenticato, inoltre, che le preparazioni dell’invenzione possono aumentare l’assorbimento degli stessi principi attivi; ciò è stato visto più in particolare con riferimento al calcio (con un aumento del tasso di digestione del 23% e del tasso di persistenza del 21%). Furthermore, it should not be forgotten that the preparations of the invention can increase the absorption of the same active ingredients; this was seen more particularly with reference to calcium (with an increase in the digestion rate of 23% and the persistence rate of 21%).
Dal punto di vista dell’attività prebiotica, le preparazioni descritte hanno mostrato una eccellente capacità proliferativa verso la flora batterica intestinale, superiore anche a quella dell’inulina. In particolare, si è notata una buona selettività nei confronti dei bifidobatteri; ciò determina un incremento dei già ottimi benefici a livello intestinale. From the point of view of prebiotic activity, the preparations described have shown an excellent proliferative capacity towards the intestinal bacterial flora, even higher than that of inulin. In particular, a good selectivity towards bifidobacteria was noted; this determines an increase in the already excellent benefits in the intestine.
Tali benefici possono riflettersi in una più bassa probabilità di sviluppare malattie intestinali, come il tumore al colon (come dimostrato da numerosi studi), o altre patologie, grazie ad un generale miglioramento della funzionalità del sistema immunitario. These benefits can be reflected in a lower probability of developing intestinal diseases, such as colon cancer (as shown by numerous studies), or other pathologies, thanks to a general improvement in the function of the immune system.
L’attività competitiva verso i microorganismi patogeni non si esplica solo nell’intestino; infatti, gli xylo-oligosaccaridi, e più in particolare gli xylo-oligosaccaridi aventi un grado di polimerizzazione inferiore a 6 e più preferibilmente compreso fra 2 e 4, competono anche con i batteri del cavo orale, specialmente gli streptococchi. Di conseguenza, le preparazioni dell’invenzione, inibiscono la proliferazione dei batteri responsabili della formazione della carie. Competitive activity towards pathogenic microorganisms is not only expressed in the intestine; in fact, xylo-oligosaccharides, and more particularly xylo-oligosaccharides having a degree of polymerization lower than 6 and more preferably between 2 and 4, also compete with bacteria of the oral cavity, especially streptococci. Consequently, the preparations of the invention inhibit the proliferation of bacteria responsible for the formation of caries.
Come ulteriore vantaggio, le preparazioni dell’invenzione hanno dimostrato di ridurre la produzione di acido lattico durante lo sforzo, giustificando ampiamente l’impiego nel settore dell’alimentazione per sportivi. As a further advantage, the preparations of the invention have been shown to reduce the production of lactic acid during exercise, amply justifying their use in the sports nutrition sector.
Nell’applicazione vaginale, le preparazioni dell’invenzione hanno dimostrato un’eccezionale stabilità ai pH bassi (2-4) tipici delle vie genitali femminili, permettendo un’efficacia ottimale dei componenti ed un rilascio graduale e temporizzato dei principi attivi. In vaginal application, the preparations of the invention have demonstrated exceptional stability at low pH (2-4) typical of the female genital tract, allowing optimal effectiveness of the components and a gradual and timed release of the active ingredients.
Il prodotto ha dimostrato di potenziare le naturali difese immunitarie, stimola e potenzia le difese organico-tissutali e la risposta immunitaria, blocca l'adesione di batteri, virus e funghi alle mucose. The product has been shown to enhance the natural immune defenses, stimulates and strengthens the organic-tissue defenses and the immune response, blocks the adhesion of bacteria, viruses and fungi to the mucous membranes.
Nell’applicazione cosmetica, le preparazioni dell’invenzione hanno dimostrato un importante e favorevole effetto carrier degli XOS sui principi attivi, favorendone la penetrazione in profondità nella pelle. In the cosmetic application, the preparations of the invention have shown an important and favorable carrier effect of XOS on the active ingredients, favoring their penetration deep into the skin.
Gli XOS riequilibrano la microflora cutanea favorendo la proliferazione di Bifidus e Lactobacilli che giocano un ruolo chiave nel processo antiinvecchiamento e rigenerativo della pelle, proteggendola e rappresentando un’ulteriore difesa immunitaria per la pelle, proteggendola da aggressioni esterne, infiammazioni e infezioni, regolandone il pH e aiutandola a contrastare la proliferazione dei batteri patogeni. XOS rebalances the skin microflora favoring the proliferation of Bifidus and Lactobacilli which play a key role in the anti-aging and regenerative process of the skin, protecting it and representing an additional immune defense for the skin, protecting it from external aggressions, inflammation and infections, regulating its pH and helping it to counteract the proliferation of pathogenic bacteria.
Le formulazioni descritte hanno, inoltre, dimostrato sorprendenti risultati nel trattamento di numerose problematiche relative ai capelli. The formulations described have also shown surprising results in the treatment of numerous hair related problems.
In ultimo, la presente invenzione consente di valorizzare sottoprodotti della pannocchia di mais, che diversamente rappresenterebbero un prodotto di scarto, con grandi vantaggi sia dal punto di vista economico sia ambientale ed ecologico, in quanto si determina una bioconversione efficiente di altrimenti recalcitranti materiali lignocellulosici. Lastly, the present invention makes it possible to exploit by-products of the corn cob, which otherwise would represent a waste product, with great advantages both from an economic, environmental and ecological point of view, since an efficient bioconversion of otherwise recalcitrant lignocellulosic materials is determined.
La persona esperta, allo scopo di soddisfare esigenze contingenti specifiche, potrà apportare modifiche, aggiunte o sostituzioni di componenti con altri funzionalmente equivalenti, senza tuttavia uscire dall’ambito delle annesse rivendicazioni. The expert, in order to meet specific contingent needs, may make changes, additions or replacements of components with other functionally equivalent ones, without however departing from the scope of the attached claims.
Ognuna delle caratteristiche descritte come appartenenti ad una possibile forma di realizzazione può essere realizzata indipendentemente dalle altre forme di realizzazione descritte. Each of the features described as belonging to a possible embodiment can be realized independently of the other described embodiments.
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102018000020383A IT201800020383A1 (en) | 2018-12-20 | 2018-12-20 | XOS corn cob derivatives to enhance the bioavailability and stability of raw materials in the production of nutraceuticals |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102018000020383A IT201800020383A1 (en) | 2018-12-20 | 2018-12-20 | XOS corn cob derivatives to enhance the bioavailability and stability of raw materials in the production of nutraceuticals |
Publications (1)
Publication Number | Publication Date |
---|---|
IT201800020383A1 true IT201800020383A1 (en) | 2020-06-20 |
Family
ID=66049466
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IT102018000020383A IT201800020383A1 (en) | 2018-12-20 | 2018-12-20 | XOS corn cob derivatives to enhance the bioavailability and stability of raw materials in the production of nutraceuticals |
Country Status (1)
Country | Link |
---|---|
IT (1) | IT201800020383A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008071930A1 (en) * | 2006-12-11 | 2008-06-19 | Danisco A/S | Composition |
WO2009117790A2 (en) * | 2008-03-25 | 2009-10-01 | Katholieke Universiteit Leuven | (arabino)xylan oligosaccharide preparation |
WO2014083166A1 (en) * | 2012-11-29 | 2014-06-05 | Nestec S.A. | Synbiotic composition and use thereof |
EP2769625A1 (en) * | 2013-02-25 | 2014-08-27 | Cargill, Incorporated | Confectionery compositions |
EP2805627A1 (en) * | 2014-09-25 | 2014-11-26 | Cargill, Incorporated | Carbohydrate compositions |
-
2018
- 2018-12-20 IT IT102018000020383A patent/IT201800020383A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008071930A1 (en) * | 2006-12-11 | 2008-06-19 | Danisco A/S | Composition |
WO2009117790A2 (en) * | 2008-03-25 | 2009-10-01 | Katholieke Universiteit Leuven | (arabino)xylan oligosaccharide preparation |
WO2014083166A1 (en) * | 2012-11-29 | 2014-06-05 | Nestec S.A. | Synbiotic composition and use thereof |
EP2769625A1 (en) * | 2013-02-25 | 2014-08-27 | Cargill, Incorporated | Confectionery compositions |
EP2805627A1 (en) * | 2014-09-25 | 2014-11-26 | Cargill, Incorporated | Carbohydrate compositions |
Non-Patent Citations (2)
Title |
---|
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; April 2016 (2016-04-01), KIM EUNJU ET AL: "Xylobiose ameliorates hyperglycemia and dyslipidemia via regulating hepatic lipogenic genes in db/db mice", XP002791067, Database accession no. PREV201700779200 * |
IKEMIZU S ET AL: "Agent for use in feed and health food for livestock for improving and preventing diarrhea, comprises acidic xylooligosaccharide having uronic acid residue in xylooligosaccharide molecule as active component", WPI / THOMSON,, vol. 2007, no. 20, 1 February 2007 (2007-02-01), XP002610643 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2879955T3 (en) | Skin aging inhibitor and resveratrol 3-O-alpha-glucoside concentrate | |
KR101768806B1 (en) | Composition comprising a fermented Araliaceae plant for anti-inflammation or anti-cancer | |
WO2010012408A3 (en) | Microemulsion | |
KR20110131498A (en) | Extracted from the shell containing the antimicrobial silver ions in alkaline solution and its composition, including manufactured | |
JP2007204423A (en) | Method for producing extract of bamboo grass and use of the extract | |
KR20190033908A (en) | Composition comprising the milk-cream fermentation product of lactic acid bacteria for preventing and improving atopic dermatitis | |
JP7458660B2 (en) | Profilaggrin mRNA expression promoter, serine palmitoyltransferase mRNA expression promoter, and hyaluronic acid synthase 3 mRNA expression promoter | |
KR101320738B1 (en) | The method of extracting carotinoid pigments of micro algae and composition comprising the extracted fucoxanthin for preventing or treating obesity or diabetes | |
KR20180106155A (en) | Whitening and moisturizing functional composition comprising a fermentation material of a natural mixture | |
JP2006265219A (en) | Diet composition | |
US20150313824A1 (en) | Skin care composition | |
JP4849792B2 (en) | Cosmetic composition | |
IT201800020383A1 (en) | XOS corn cob derivatives to enhance the bioavailability and stability of raw materials in the production of nutraceuticals | |
JPWO2005042555A1 (en) | Tyrosinase activity inhibitor and facial blood flow improving agent | |
US20160022556A1 (en) | 1,5-anhydro-d-glucitol-containing collagen production accelerator | |
KR101757841B1 (en) | Composition for inhibiting obesity comprising complex salt of baicalin and zinc | |
JP7130900B2 (en) | Composition | |
US20070275150A1 (en) | Nutritional composition and method of making the same | |
US20220370539A1 (en) | 5a-REDUCTASE INHIBITOR | |
WO2017146560A1 (en) | Anti-aging supplement | |
JP2010270021A (en) | Ucp gene expression-promoting agent | |
KR101755017B1 (en) | Method for preparation of extracts of Dudleya brittonii and composition for anti-cancer or anti-oxidation comprising the extracts of Dudleya brittonii as active ingredient | |
JP2008007406A (en) | Fat metabolism promoter | |
WO2020079641A1 (en) | Compositions comprising essential oils and/or hydrolates from plants of italian origin and the use thereof for the treatment of gastrointestinal and genitourinary disorders | |
KR20140018596A (en) | Composition for anti oxidation containing extract of soybean pod |